For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies stabilize the transthyretin protein, preventing its destructive build-up and alleviating the severity of the condition . Patients are